$29.37+0.37 (+1.28%)
Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. in the Healthcare sector is trading at $29.37. Wall Street consensus targets $45.10 (10 analysts), implying a +53.6% move over the next 12 months. The stock is currently 27% below its 52-week high of $40.22, remaining 3.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisen...
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds. On May 7, Stoke Therapeutics, Inc. (NASDAQ:STOK) reported Q1 results and business updates. The company stated that four years of data from “Phase 1/2a open-label extension” studies revealed statistically meaningful gains in cognition and behavior, […]
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its latest quarterly results and things are looking bullish...
Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label extension data, while the company remains on track to complete enrollment in its pivotal Pha